The CEO of the German biotech CureVac, Franz-Werner Haas, said Thursday that they plan to produce between 300 and 400 million doses of their coronavirus vaccine in 2021, as reported by Reuters.
Featured Comments:
“Vaccination against COVID-19 is not expected to be repeated every year.”
“Currently, the coronavirus does not appear to mutate as much as the seasonal flu.”
“We are currently talking to several potential important partners who could support us“.
“The vaccine is a suitable candidate for standard refrigerator temperature logistics.”
“The candidate vaccine data supports at least three months of stability at + 5ºC (+ 41ºF).”
“We have verified up to 24 hours of established stability at room temperature.”
.
Credits: Forex Street
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
